The molecular biology of thrombotic microangiopathy

Kidney International

Volumn 70, Issue 1, 2006, Pages 16-23

  Tsai, H M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

ADAMTS13; Hemolytic uremic syndrome; Regulators of complement activation; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura; Von Willebrand factor

Indexed keywords

AUTOANTIBODY; FIBRINOGEN; MEMBRANE COFACTOR PROTEIN; SHIGA TOXIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL CELL; ANIMAL TISSUE; AUTOIMMUNITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GENE MUTATION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HOMEOSTASIS; HUMAN; HYALINE DEGENERATION; MOLECULAR BIOLOGY; MOUSE; NEUROLOGICAL COMPLICATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SYNDROME DELINEATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ANIMALS; ANTIGENS, CD46; COMPLEMENT FACTOR H; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MICE; MICROCIRCULATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 33745683637     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001535     Document Type: Short Survey

References (21)

1. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006; 57: 419-436.
2. Dong JF, Moake JL, Nolasco L et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
3. Motto DG, Chauhan AK, Zhu G et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761.
4. Bonnefoy A, Daenens K, Feys HB et al. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS-13. Blood 2006; 107: 955-964.
5. Zhou W, Dong L, Ginsburg D et al. Enzymatically-active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies - a novel therapeutic strategy? J Biol Chem 2005; 280: 39934-39941.
6. Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 2003; 101: 4449-4451.
7. Bestetti G, Stellari A, Lattuada A et al. ADAMTS 13 genotype and vWF protease activity in an Italian family with TTP. Thromb Haemost 2003; 90: 955-956.
8. Plaimauer B, Fuhrmann J, Mohr G et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino-acid polymorphisms and a missense mutation. Blood 2006; 107: 118-125.
9. Noris M, Bucchioni S, Galbusera M et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005; 16: 1177-1183.
10. Rieger M, Mannucci PM, Kremer Hovinga JA et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-1267.
11. Tsai HM, Raoufi M, Zhou W et al. ADAMTS13-Binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006 (in press).
12. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086.
13. Obrig TG, Del Vecchio PJ, Brown JE et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 1988; 56: 2373-2378.
14. Tsai HM, Chandler WL, Sarode R et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49: 653-659.
15. Nolasco LH, Turner NA, Bernardo A et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005; 106: 4199-4209.
16. Dragon-Durey MA, Fremeaux-Bacchi V. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol 2005; 27: 359-374.
17. Fremeaux-Bacchi V, Kemp EJ, Goodship JA et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005; 42: 852-856.
18. Dragon-Durey MA, Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563.
19. Levy M, Halbwachs-Mecarelli L, Gubler MC et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30: 949-956.
20. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15: 787-795.
21. Vyse TJ, Spath PJ, Davies KA et al. Hereditary complement factor I deficiency. Q J Med 1994; 87: 385-401.